Veradermics, Incorporated (MANE)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | - | 0 | 0 | 0 | 0 | - |
| Operating profit | $m | -72 | -82 | ||||||
| Net profit | $m | - | - | - | -16 | -26 | -70 | -73 | -100 |
| EPS reported | $ | -2.00 | -2.14 | ||||||
| Operating cashflow per share | $ | -2.04 | -1.47 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -2.04 | -1.47 | ||||||
| Free cash flow | $m | -72 | -59 | ||||||
| Net debt | $m | -142 | -820 | ||||||
| Book value equity | $m | -121 | - | ||||||
| Book value per share | $ | -3.45 | 20.12 | ||||||
| Number of shares | m | 35.08 | 40.44 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -10.94 | 5.60 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -18.49 | -22.33 | ||||||
| EV/EBITDA LTM | x | -18.61 | -16.68 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -5.29% | -1.59% | ||||||
| FCF Yield | % | -5.41% | -4.48% | ||||||
| Quality | |||||||||
| ROE | % | +57.84% | -29.37% | ||||||
| ROIC | % | -50.43% | -10.13% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -17,906.50 | -138.58 | ||||||
| Net Debt/EBITDA | x | 0.31 | 4.08 | ||||||
| EBIT/Net interest | x | 0.00 | -154.94 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | 1.17 | - | ||||||
| Gross debt/equity | x | -0.00 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free